6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2019

Commission File Number: 001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

Bâtiment Adénine, 60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒  Form 20-F            ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

ERYTECH Pharma S.A. (the “Company”) is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statements of financial position as of June 30, 2018 and (ii) unaudited interim condensed consolidated statements of income (loss) for the six months ended June 30, 2018, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.

EXHIBIT LIST

Exhibit	Description
99.1	Unaudited Interim Condensed Consolidated Statements of Financial Position as of December 31, 2017 and June 30, 2018
99.2	Unaudited Interim Condensed Consolidated Statements of Income (Loss) for the Six Months Ended June 30, 2017 and 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ERYTECH Pharma S.A.
Date: January 4, 2019	By:	/s/ Eric Soyer
	Name	Eric Soyer
	Title:	Chief Financial Officer and Chief Operating Officer

EX-99.1

Exhibit 99.1

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Amounts in thousands of euros)

	As of
	June 30, 2018		December 31, 2017
	€		€
ASSETS
Non-current assets
Intangible assets		1,629		53
Property, plant and equipment, net		2,759		3,406
Other non-current financial assets		852		234
Total non-current assets		5,241		3,693
Current assets
Inventories		259		176
Trade and other receivables				76
Other current assets		11,237		5,791
Cash and cash equivalents		165,421		185,525
Total current assets		176,916		191,568
TOTAL ASSETS		182,156		195,261
	As of
	June 30, 2018		December 31, 2017
LIABILITIES AND SHAREHOLDERS’ EQUITY		€		€
Shareholders’ equity
Share capital		1,794		1,794
Premiums related to share capital		281,745		281,785
Reserves		(100,567)		(68,346)
Translation reserve		(190)		(203)
Net loss for the period		(18,970)		(33,530)
Total shareholders’ equity		163,812		181,419
Non-current liabilities
Long-term provisions		322		214
Financial liabilities – non-current portion		1,630		2,019
Deferred tax				3
Total non-current liabilities		1,952		2,236
Current liabilities
Financial liabilities – current portion		796		824
Trade and other payables		12,366		8,076
Other current liabilities		3,231		2,706
Total current liabilities		16,392		11,606
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		182,156		195,261

EX-99.2

Exhibit 99.2

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Amounts in thousands of euros, except per share amounts)

	Six Months Ended         June 30,
	2018		2017
	€		€
Operating income
Revenues
Other income		2,265		1,788
Total operating income		2,265		1,788
Operating expenses
Research and development		(16,752)		(12,082)
General and administrative		(7,393)		(3,895)
Total operating expenses		(24,145)		(15,977)
Operating loss		(21,880)		(14,189)
Financial income		2,966		160
Financial expenses		(42)		(47)
Financial income		2,924		114
Income tax		(14)		(5)
Net loss		(18,970)		(14,081)
Basic / diluted loss per share (€/share)		(1.06)		(1.42)